ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q1Scopus Q1SCImago #897Hybrid

Biodrugs

Acronym:bdra
•
Abbreviation (ISO):BIODRUGS
•
Identifier (ISSN):1173-8804(Print)/1179-190X(Online)
•
Publisher:Springer International Publishing
Clarivate IF (2026)
8.5↑ +1.6
Journal Impact Factor
IF Trend↓
WoS Quartile
Q1
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Biodrugs

WoS Q1
258113.8320184.920195.3120205.8120217.7420226.820235.420246.920258.52026
Annual Impact Factor Metric
Current (2026):8.5
Scopus SJR & RankScopus Q1
2.628
#897

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
90

90 papers with at least that number of citations each

WoS: SCIE / JCRQ1
Self-Citation Rate5.6%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
47articles/year
57.31% Gold OA•58.18% Original Research

Aims & Scope

An essential resource for R&D professionals and clinicians with an interest in biologic therapies. BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

Topics Covered (Recognized by AI)
Medicine97.5%Biology95.4%Internal medicine86%Genetics77.8%Immunology62.7%Pathology55.7%Chemistry51.6%Biochemistry47.3%Pharmacology41.8%Surgery33.7%Psychology30.9%Endocrinology27.7%Psychiatry27.2%Bioinformatics25.8%Disease25.4%Immune system23.4%Antibody23.3%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

IMMUNOLOGY

Q1
Rank19/183
IndexSCIE
JCRSCIE2026

ONCOLOGY

Q1
Rank40/333
IndexSCIE
JCRSCIE2026

PHARMACOLOGY & PHARMACY

Q1
Rank19/356
IndexSCIE
JCISCIE2026

IMMUNOLOGY

Q1
Rank31/183
IndexSCIE
JCISCIE2026

ONCOLOGY

Q1
Rank55/333
IndexSCIE
JCISCIE2026

PHARMACOLOGY & PHARMACY

Q1
Rank44/356
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF8.5
Articles / Year52
Total Citations23
2025
IF6.9
Articles / Year61
Total Citations429
2024
IF5.4
Articles / Year58
Total Citations859
2023
IF6.8
Articles / Year66
Total Citations1,805
2022
IF7.744
Articles / Year60
Total Citations1,824

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #897Scopus Q1SCImago Profile
Scopus Coverage:1996-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q1
2.628

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1
Citations / Doc (2 years)
8.60

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,776 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,474
3-Year Documents169
Citable Documents165

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate45.7%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

BiotechnologyQ1
Medicine (miscellaneous)Q1
PharmacologyQ1
Pharmacology (medical)Q1
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 5.6%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
2区 (Zone 2)Medicine
Minor Category (Specific Field):
2区ONCOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Biodrugs (acronym: bdra, abbr: BIODRUGS, ISSN: 1173-8804) is a peer-reviewed international scholarly journal in the field of Medicine, published by Springer International Publishing in New Zealand since 1994. The periodical holds a Journal Impact Factor (JIF) of 8.50, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 2.628 (Q1), an H-index of 90.

The journal enforces rigorous peer evaluation with a publication frequency of Bimonthly, an annual output of approximately 47 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,776 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Springer International Publishing
Publication Language
English
Frequency
Bimonthly
Founding Year
1994
Indexing & Databases
SCIEScopusPubMed
Editorial Address
ADIS INT LTD, 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND, NEW ZEALAND, 1311

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 5536b5ed-a821-4ea7-bed2-7d18f879ff33
Database Updated: 2026-10-01